Innoviva Operating Expenses 2010-2024 | INVA
Innoviva operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Innoviva Annual Operating Expenses
(Millions of US $) |
| 2024 |
$192 |
| 2023 |
$197 |
| 2022 |
$-142 |
| 2021 |
$17 |
| 2020 |
$16 |
| 2019 |
$15 |
| 2018 |
$23 |
| 2017 |
$34 |
| 2016 |
$25 |
| 2015 |
$22 |
| 2014 |
$42 |
| 2013 |
$33 |
| 2012 |
$31 |
| 2011 |
$134 |
| 2010 |
$103 |
| 2009 |
$106 |
Innoviva Quarterly Operating Expenses
(Millions of US $) |
| 2024-12-31 |
$49 |
| 2024-09-30 |
$46 |
| 2024-06-30 |
$45 |
| 2024-03-31 |
$52 |
| 2023-12-31 |
$48 |
| 2023-09-30 |
$49 |
| 2023-06-30 |
$52 |
| 2023-03-31 |
$46 |
| 2022-12-31 |
$42 |
| 2022-09-30 |
$-222 |
| 2022-06-30 |
$26 |
| 2022-03-31 |
$12 |
| 2021-12-31 |
$3 |
| 2021-09-30 |
$3 |
| 2021-06-30 |
$4 |
| 2021-03-31 |
$6 |
| 2020-12-31 |
$6 |
| 2020-09-30 |
$4 |
| 2020-06-30 |
$3 |
| 2020-03-31 |
$3 |
| 2019-12-31 |
$2 |
| 2019-09-30 |
$5 |
| 2019-06-30 |
$4 |
| 2019-03-31 |
$3 |
| 2018-12-31 |
$3 |
| 2018-09-30 |
$4 |
| 2018-06-30 |
$4 |
| 2018-03-31 |
$12 |
| 2017-12-31 |
$3 |
| 2017-09-30 |
$9 |
| 2017-06-30 |
$11 |
| 2017-03-31 |
$11 |
| 2016-12-31 |
$6 |
| 2016-09-30 |
$5 |
| 2016-06-30 |
$7 |
| 2016-03-31 |
$7 |
| 2015-12-31 |
$6 |
| 2015-09-30 |
$5 |
| 2015-06-30 |
$6 |
| 2015-03-31 |
$6 |
| 2014-12-31 |
$7 |
| 2014-09-30 |
$11 |
| 2014-06-30 |
$11 |
| 2014-03-31 |
$14 |
| 2013-12-31 |
$-18 |
| 2013-09-30 |
$8 |
| 2013-06-30 |
$8 |
| 2013-03-31 |
$35 |
| 2012-12-31 |
$36 |
| 2012-09-30 |
$35 |
| 2012-06-30 |
$37 |
| 2012-03-31 |
$41 |
| 2011-12-31 |
$41 |
| 2011-09-30 |
$36 |
| 2011-06-30 |
$30 |
| 2011-03-31 |
$28 |
| 2010-12-31 |
$25 |
| 2010-09-30 |
$25 |
| 2010-06-30 |
$26 |
| 2010-03-31 |
$27 |
| 2009-12-31 |
$24 |
| 2009-09-30 |
$27 |
| 2009-06-30 |
$27 |
| 2009-03-31 |
$28 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.132B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
